Navigation Links
Increased glucose level is a strong risk factor for colorectal cancer
Date:11/1/2007

Bethesda, MD (November 1, 2007) Diabetes is a very common illness that affects more than 20 million people in the U.S. and it is estimated an additional 54 million Americans have pre-diabetes, a condition that occurs when a person's blood glucose levels are higher than normal but not high enough for a diagnosis of type 2 diabetes. Therefore, it is important to determine whether glucose and insulin levels are associated with a higher risk of colon polyps, the precursor lesions to colon cancer. According to the results of a study published in Gastroenterology, patients with high levels of insulin and glucose are at increased risk of developing recurrent colorectal adenomas, or tumors, with elevated glucose providing the strongest risk factor for recurrence of these lesions.

This is the first study to determine whether elevated glucose or insulin as measured when or shortly after a patient has had polyps removed during a baseline colonoscopy procedure increases their risk for subsequent recurrence of pre-cancerous growths in the colon, according to Andrew Flood, PhD, of the University of Minnesota and lead author of the study. The results of our study have important clinical implications with respect to maintenance of glycemic control in patients with a history of colorectal polyps.

In particular, study subjects who had even modestly impaired fasting glucose (an early sign of insulin resistance, itself a precursor of diabetes) had an especially large increased risk of recurrence of the types of polyps that are most likely to progress to invasive cancer. Therefore, the clinical management of glycemic control is important in reducing the risk of tumor recurrence and colorectal cancer. The glucose levels observed by researchers in the Polyp Prevention Trial, of which this study was a subset analysis, and the levels of exposure that led to the increased risk, were not unusually elevated. Researchers used a glucose concentration of 99 mg/dl as the cut point for the patients in the high group in the study; a fasting blood glucose level between 100 and 125 mg/dl signals pre-diabetes. The levels used in the study are reflective of those in the general U.S. population, therefore it is important to note that even a modest elevation of fasting glucose can affect a patients risk of colorectal cancer.

Patients who presented with the highest levels of both insulin and glucose had an approximately 50 percent increased risk of colorectal tumor recurrence. The Polyp Prevention Trial found a recurrence for colorectal tumors of 39.6 percent over four years, meaning the recurrence rate in this subset of patients represents a large increase in absolute risk. Patients who had a high concentration of glucose experienced more than 2.4 times increased odds of advanced tumor recurrence. The subjects with the highest glucose concentration also tended to be slightly older and have higher body mass index (BMI) and waist to hip ratios. Additionally, they were more likely to be male, current smokers, a member of a minority group and less likely to have advanced beyond a high school education. For those without a family history of colorectal cancer, researchers observed an even greater risk with elevated concentrations of insulin and glucose compared to the overall study population.

More than 1,905 patients from the Polyp Prevention Trial completed the study protocol, of which 375 matched pairs, or 750 patients, were included in this subset analysis. The patients were matched for gender and age within five years among trial participants who had recurrent adenomas and stored serum. The Polyp Prevention Trial was a clinical trial headed by the National Cancer Institute conducted with 2,079 men and women to determine the effect of a low-fat, high-fiber, high fruit/vegetable eating plan on the recurrence of precancerous polyps in the colon and rectum. Every participant had been diagnosed with a polyp within the previous six months, which was removed at colonoscopy.


'/>"/>

Contact: Aimee Frank
media@gastro.org
301-941-2620
American Gastroenterological Association
Source:Eurekalert

Related medicine news :

1. Use of Cellular Phones associated with Increased risk of Brain Tumors
2. Mortality increased in Sporting enthusiasts!
3. Increased Heart Attack Risk From Celebrex,Vioxx
4. Allergy Risk Increased by Kerosene Use
5. Strokes increased during squatting
6. Asthmatics at increased risk of lung cancer
7. Renal problem increased
8. Fewer teeth & Increased Ischemic Stroke risk
9. Risk of hemorrhagic stroke increased in smoking individuals
10. Young Smokers at Increased Risk Of Developing a Heart Attack
11. Women With Diabetes At Increased Risk Of Developing Cognitive Impairment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ... October 12, 2017 , ... CitiDent and ... apnea using cutting-edge Oventus O2Vent technology. As many as 18 million Americans ... frequent cessation in breathing. Oral appliances can offer significant relief to about 75 ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... ... products to meet the demand of today’s consumer and regulatory authorities worldwide. From ... probiotic experts and tested to meet the highest standard. , These products ...
(Date:10/12/2017)... ... ... The American College of Medical Informatics (ACMI) will present the 2017 Morris ... of AMIA’s Annual Symposium in Washington, D.C. AMIA’s Annual Symposium is taking ... in the field of medical informatics, this prestigious award is presented to an individual ...
(Date:10/12/2017)... ... October 12, 2017 , ... Information ... we intend to develop to enable prevention of a major side effect of ... loss, especially in pediatric patients. For cisplatin, hearing loss is FDA listed on-label ...
(Date:10/12/2017)... ... October 12, 2017 , ... HMP , a leader ... a 2017 Folio Magazine Eddie Digital Award for ‘Best B-to-B Healthcare Website.’ Winners were ... 11, 2017. , The annual award competition recognizes editorial and design excellence across a ...
Breaking Medicine News(10 mins):
(Date:10/2/2017)... 2, 2017  AllianceRx Walgreens Prime, the combined central ... and pharmacy benefit manager Prime Therapeutics LLC (Prime), today ... included the unveiling of new signage at its headquarters ... as at a few other company-owned facilities across the ... patients, some of whom will begin to see the ...
(Date:9/28/2017)... -- Cohen Veterans Bioscience and Early Signal Foundation announce ... home sensors for real-time monitoring of patients with trauma-related ... organization focused on disruptive health solutions for rare disorders ... to record and integrate behavioral, cognitive, physiological and contextual ... ...
(Date:9/25/2017)...  EpiVax, Inc., a leader in the fields ... announced the launch of EpiVax Oncology Inc., a ... cancer vaccines. EpiVax has provided $500,000 in seed ... technologies to the new precision immunotherapy venture. Gad ... as Chief Executive Officer. Gad brings over 25 ...
Breaking Medicine Technology: